Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$14.32 USD
0.00 (0.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.24 -0.08 (-0.56%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KROS 14.32 0.00(0.00%)
Will KROS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KROS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KROS
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
KROS: What are Zacks experts saying now?
Zacks Private Portfolio Services
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Other News for KROS
ClearBridge Small Cap Strategy Q2 2025 Commentary
Noteworthy Friday Option Activity: KROS, TEAM, BYON
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
Major Shareholder Sells Off Keros Therapeutics Stock!
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls